76 related articles for article (PubMed ID: 23326955)
1. Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
Popescu C; Gliga S; Aramă V
Rom J Intern Med; 2012; 50(2):117-27. PubMed ID: 23326955
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH
Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426
[TBL] [Abstract][Full Text] [Related]
3. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
Venkatraman S
Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
Matthews SJ; Lancaster JW
Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
[TBL] [Abstract][Full Text] [Related]
5. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
[TBL] [Abstract][Full Text] [Related]
6. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
7. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G
J Pharm Biomed Anal; 2013 May; 78-79():217-23. PubMed ID: 23501442
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
Trembling PM; Tanwar S; Dusheiko GM
Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Hézode C
Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
[TBL] [Abstract][Full Text] [Related]
10. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
11. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
12. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S
Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799
[TBL] [Abstract][Full Text] [Related]
13. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
14. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
15. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
Welsch C; Jesudian A; Zeuzem S; Jacobson I
Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
[TBL] [Abstract][Full Text] [Related]
16. [Direct antiviral treatment strategies in chronic hepatitis C].
Neumann-Haefelin C; Blum HE; Thimme R
Dtsch Med Wochenschr; 2012 Jun; 137(25-26):1360-5. PubMed ID: 22653493
[TBL] [Abstract][Full Text] [Related]
17. Boceprevir.
Prescrire Int; 2012 Apr; 21(126):89-92. PubMed ID: 22515132
[TBL] [Abstract][Full Text] [Related]
18. [New treatments for hepatitis C, which targets, what timeline?].
Goossens N; Negro F
Rev Med Suisse; 2011 Sep; 7(307):1683-8. PubMed ID: 21987876
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C and substance use: new treatments and novel approaches.
North CS; Hong BA; Kerr T
Curr Opin Psychiatry; 2012 May; 25(3):206-12. PubMed ID: 22395769
[TBL] [Abstract][Full Text] [Related]
20. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
